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Recently, alternative therapies are gaining popularity in the treatment of epilepsy. The
present study aimed to find out the antiepileptic potential of quercetin, catechin, and
kaempferol. In vivo and in silico experiments were conducted to investigate their
therapeutic potential. 25 mg/kg/day of pentylenetetrazole was administered for
4 weeks after epilepsy was induced in the rats; this was followed by the behavioral
studies and histological analysis of rat brain slices. Binding affinities of kaempferol,
quercetin, and catechin were assessed by performing in silico studies. Kaempferol,
quercetin, and catechin were found to have the highest binding affinity with the
synaptic vesicle 2A (SV2A) protein, comparable to standard levetiracetam (LEV). The
mRNA levels of SV2A, as well as the expression of TNF, IL 6, IL 1 beta, NFkB, IL 1Ra, IL 4,
and IL 10, were investigated using qPCR. Our results indicate for the first time that SV2A is
also a transporter of understudied phytoflavonoids, due towhich a significant improvement
was observed in epileptic parameters. The mRNA levels of SV2A were found to be
significantly elevated in the PF-treated rats when compared with those of the control rats
with epilepsy. Additionally, downregulation of the pro-inflammatory cytokines and
upregulation of the anti-inflammatory cytokines were also noted in the PF-treated
groups. It is concluded that kaempferol, quercetin, and catechin can effectively
decrease the epileptic seizures in our chronic epilepsy rat model to a level that is
comparable to the antiepileptic effects induced by levetiracetam drug.
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INTRODUCTION
Epilepsy is a neurological disorder that is characterized by
recurrent malicious seizures, which are varied in occurrence
and severity (Szilágyi et al., 2014). In vivo and in vitro studies
have shown that both flavonoid- and non–flavonoid-containing
plants have the potential to improve morbidity in epilepsy
(Majeed et al., 2019). Different antiepileptic drugs (AEDs)
have been reported with serious side effects along with the
development of resistance against the currently available AEDs
(Chen et al., 2017; Ramalingam et al., 2013). First-generation
AEDs include: carbamazepine, phenobarbital, and valproic acid,
while lamotrigine, vigabatrin, tiagabine, topiramate, gabapentin,
and levetiracetam (LEV) are classified as second-generation drugs
(Ahmad et al., 2017). These drugs exert their antiepileptic effects
by modulating ionotropic GABA-A, glutamate receptors,
synaptic vesicle 2 A (SV2A) transporters, and ion channels
such as Na+, Ca++, and K+ (Noachtar et al., 2008; Leclercq et
al., 2020). This eventually results in the fluctuation of the firing
properties of neurons (Verrotti et al., 2020). LEV exhibits its
antiepileptic effect via inhibition of excessive synchronized
activity between neurons. Padsevonil (novel antiepileptic drug)
has more affinity for SV2A than levetiracetam and brivaracetam.
LEV employs its therapeutic effect by binding to SV2A (Patel
et al., 2006). LEV is used to treat refractory status epilepticus
(Patel et al., 2006), status epilepticus (Rossetti and Bromfield,
2006), and acute and generalized idiopathic myoclonic epilepsy in
neonates as well in adults (Khan et al., 2011). LEV has a high
affinity for the SV2A receptor, where it binds and modulates the
receptor. It has been observed that SV2A does not play a role in
biogenesis or synaptic function, but it modulates exocytosis of
transmitter-containing vesicles (Mendoza-Torreblanca et al.,
2019). To understand the epileptogenesis and discovery of
novel AEDs, chemically kindled epileptic models in rats have
been developed. The chemically kindled animals are exposed to
sub-conclusive chemical stimuli. When the chemical is applied
repetitively and intermittently, it ultimately leads to the
generation of complete convulsions (Lynch et al., 2004). PTZ
antagonizes the glycine amino butyric acid (GABA)-A receptor
that leads to the development of seizures in rats (Hansen et al.,
2004; Badawi et al., 2021).
It has been reported that brain inflammation contributes to the
etiopathogenesis of seizures and the establishment of chronic
epilepsy (Ambrogini et al., 2019). Inflammatory cytokines (IL-1β,
TNF-α, and IL-6) and non-inflammatory cytokines (IL1Ra, IL-
10, and IL-4) overexpressed and underexpressed, respectively, in
experimentally induced seizures at the seizure generation and
propagation sites in the brain (Vezzani et al., 2011). Similarly,
NFkB, which is a transcription factor, is up-regulated in seizure
states. The cytokine receptors are also up-regulated and down-
regulated accordingly (Maroso et al., 2010). This type of kindling
produces foci in the rat’s hippocampus (Dhir, 2012). There is an
association between cytokines and neurotransmitters. The
neuronal excitability is cytokine-mediated; hence, it
ameliorates the disease conditions (Vezzani et al., 2008). The
electrical and chemical kindling models are the most frequently
used kindling models. Of these, the most famous model is the
chemical kindling model. This model is developed by using sub-
conclusive doses of any convulsant chemical, which results in the
chronic stimulation of cerebral neurons. Hence, chronic
stimulation leads to impulsive seizures (Vrinda et al., 2017).
Moreover, electrical kindling can also cause chronic
stimulation of neuronal cells by sub-conclusive electrical
stimulus, which can cause unprompted generalized convulsions.
Natural products have always been a treatment of interest as an
alternative to the available allopathic treatments. In this regard,
phytoflavonoids (PFs) have been tested in fully kindled animals.
However, studies regarding the clinical pharmacokinetic and
pharmacodynamic effects of these flavonoids are scarce.
Therefore, studies investigating the active constituents from such
medicinal plants as well as their mechanism of action are critical.
In the present study, kaempferol, quercetin, and catechins
(phytoflavonoids) are used to identify their potential
antiepileptic effect in a rat model. These phytoflavonoids are the
constituents of most of the plants that are reported to have
antiepileptic potential (Moghbelinejad et al., 2016). These PFs
have been shown to be effective against epilepsy, and
Alzheimer’s and Parkinson’s diseases (Farooqui and Farooqui,
2012). Catechin protects the brain from producing beta-amyloid
protein that results in the deposition of amyloid plaques and
memory impairment in Alzheimer’s (Conte et al., 2003), while
quercetin’s mechanism of action is unknown; however, it has been
shown to be effective in temporal lobe epilepsy (Moghbelinejad
et al., 2016). Kaempferol is reported to have antidiuretic and
antiarrhythmic potential to cure as well as prevent from
counteracting human immune virus 1 (HIV 1) infection
(Behbahani et al., 2014).
MATERIALS AND METHODS
Materials
LEV (Batch number L16102017) from Wuhan Demeikai
Biotechnology Co., Ltd; quercetin (Batch number
HK20181225) from Shaanxi Huike Botanical Development
Co., Ltd., P.R. China; kaempferol (Batch number
HK20180320) from Shaanxi Huike Botanical Development
Co., Ltd., P.R. China; catechin (Batch number 204CELK04)
from Sigma-Aldrich, Germany, pentylenetetrazole (PTZ)
(Batch number SLBD3876V) from Sigma-Aldrich, Germany;
and IR actimeter from Panlab, Harvard apparatus, Barcelona,
Spain, were obtained.
In this study, in silico evaluation was carried out to explore the
possible binding mechanism of PFs with the SV2A receptor. After
the in silico studies confirmed the binding of PFs with the SV2A
receptor, the in vivo studies were performed in the chronic
epilepsy rat model to establish the proof of concept as well as
find confirmation of our in silico study. In order to identify the
possible mechanism behind the epileptic treatment in our rat
model, we also investigated the expression levels of pro- and anti-
inflammatory cytokines in the blood of our rat models.
Study Design
Figure 1 outlines the study design.
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In Silico Studies
Ligand Preparation and Docking Studies
The co-crystal structure of the SV2A receptor (PDB entry: 4V11),
sodium channel (PDB entry: 6AGF), and GABA-A (PDB entry:
6D6T) receptors were retrieved from the RCSB Protein Data Bank.
After generating the 3Dmodel and structure, stereochemical analyses
were performed using different evaluations and validation tools. All
the molecules were neutralized by removing water molecules. The
Psi/Phi Ramachandran plot was obtained using PROCHECK
(Laskowski et al., 1993). The 3D structure of LEV and PFs was
constructed using the Sybyl-X1.3/SKETCH module (Jain, 2003).
Molecular Dynamic Simulations
The final complexes of LEV and PFs bound to the SV2A receptors
were subjected to molecular dynamic (MD) simulations for
further stabilization and refinement. All MD simulations were
thoroughly performed in PyRx, PyMol, and Autodock software
packages (Case et al., 2016).
Free Energy Calculation
Binding energies of the selected compound with SV2A
complexes were determined. Initially, the equilibrium
confirmations for the complex, free receptor, and free
ligands were prepared, and after that, the binding free
energy was calculated.
Animals
Male Albino rats (weighing 180–220 g) were purchased from the
animal house and were kept under standard laboratory
conditions (temperature 25 ± 3°C, humidity 55 ± 5%, and 12 h
light and dark cycle). All rats had free access to the standard diet
and water.
The rats were randomly divided into six groups (seven rats
in each group): normal (Group 1), diseased (Group 2),
standard drug (Group 3, LEV 21 mg/kg od), kaempferol
(Group 4, 100 mg/kg od), quercetin (Group 5, 100 mg/kg
od), and catechin (Group 6, 100 mg/kg od) treated groups.
The doses of PFs were chosen based on the literature as the
most effective doses to exert the desired pharmacological
effects (Diniz et al., 2015).
Chemical Kindled Model of Epilepsy
The rats were injected intraperitoneally (i.p.) with the sub-
conclusive dose of PTZ (25 mg/kg) for 28 days (Yu et al., 2013).
Clinical Scoring
The intensity of seizure response was scored according to the
scale described as follows (Yao et al., 2012): 0 (no response), 1
(mouth and facial jerks), 2 (nodding or myoclonic body jerks),
3(forelimb clonus), 4 (rearing, falling down, hind limb clonus,
and forelimb tonus), and 5 (tonic extension of hind limb or
death).
The maximum response was recorded for each animal. Only
those animals that maintained a minimum threshold score of 2 in
at least five consecutive episodes or a score of 4 or 5 in three
consecutive seizure episodes were considered to be the kindled
rats (da Silva Ferreira, 2018). The treatment was carried out from
day 29 until day 43.
FIGURE 1 | Showing the study design.
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Parameters
The following parameters were noted during the observation time
(360 min after the injection) on days 0, 7, and 14: delay in the
onset of seizures (Singh and Goel, 2009), intensity of seizures,
average number of seizures, and duration of seizures, while the
maximum time frame was up to 360 min, percentage protection
of seizures (Garip Ustaoglu et al., 2018).
Behavioral Tests
The behavioral tests were performed in all groups before and after
the induction of epilepsy. Only the animals that met the
minimum criteria of the study were considered for behavioral
testing. Each animal was housed in an individual plastic cage
during the study period. All behavioral tests were performed in a
closed, quiet, light-controlled room, and the results were analyzed
by an investigator blinded to the treatment.
Light and Dark Model
The apparatus consisted of an open-top wooden box with two
distinct chambers, one (20 × 30 × 35 cm) darkened with black
paint and another (30 × 30 × 35 cm) brightly illuminated with a
white light source. Both the chambers were connected through a
small open doorway (7.5 × 5 cm) (Gupta and Sharma, 2019).
Each rat was placed individually in the center of the light chamber
and observed for 5 min. The time spent in the light and dark
chambers was recorded (Singh et al., 2019).
Elevated Plus Maze
The elevated plus maze (EPM) was made up of a wooden arena,
with two opposite arms having 30 cm high walls, while the other
two arms were exposed. Each arm has a width of 13 cm and
length of 43.5 cm; the maze was elevated 60 cm above the floor.
The training protocol used for the behavioral testing has been
reported elsewhere (Tanila et al., 1997). The training was carried
to ensure that the animals were previously familiarized with the
single-trial procedure and that their choice was reinforced
regardless of the arm selected. The training was carried out in
the regular morning and afternoon sessions for 15 days.
Each rat was placed in the middle of the EPM, and the total
time spent in each arm during the 300 s trial was recorded
(Tchekalarova et al., 2014).
Rotarod Test
The rotarod apparatus consisted of a roller of 8 cm diameter,
separated into wide compartments of 9 cm, and are raised at
16 cm (Oleas et al., 2013). The rats were trained for 3 days: on the
first day, over 1 min for four (Chen et al., 2017) times; on the
second day, over 1 min for four (Chen et al., 2017) times and
20 rpm; and on the third day, the rotarod accelerated to 40 rpm
over 5 min (Jurado-Arjona et al., 2019). The latency to fall was
measured during the accelerating trials. The latency to fall was
recorded, and the total latencies on the rod on each day were
analyzed. Next, to compare the typical rotarod test with our
modified rotarod test, we also tested the accelerating rotarod
protocol (ref). The speed of the rod was accelerated from 10 to
40 rpm. The habituation time and daily schedule were the same
(Shiotsuki et al., 2010).
The rats were positioned on the rod of rotarod and tested with
different rotational speeds for 2 min at each speed, beginning at
the slowest usually 10 rpm and increasing progressively. The
length of time that each animal can remain on the rod at a
given rotational speed was observed. The test was performed on
several rats in the same session. Usually, after each session, the rat
is rested for about 20–30 min, to reduce stress and fatigue (Arcuri
et al., 2016).
Infrared Actimeter
The IR frame where the experimental subjects were placed had a
dimension of 45 × 45 cm. It contains a total of 16 × 16 IR beams at
an interval of 2.5 cm located on the sides. There were a total of 32
cells in each frame. The frame is attached with a control unit/data
logger, which is manufactured by Panlab, Harvard apparatus,
Barcelona, Spain. This apparatus has a unique ability to identify
the slow as well as fast movements of the rat placed inside the
frame (Yaroslavsky et al., 2019).
The individual rat was placed in the frame for 5 minutes and
turned on the data logger (Machado et al., 2012). The data logger
counts both slow movements and fast movements of the rat with
the help of infrared rays (Busquets et al., 2018). It was found that
the diseased rats displayed more slow movements, while the
normal healthy rats showed more fast movements
comparatively (Studer et al., 2019) (Machado et al., 2012).
Beam Walking Test
The beam walking test (BWT) is widely used to evaluate motor
coordination and balance in rat models. It consists of a wooden
beam (1 m) which is round of shape (5 mm diameter) and
elevated 50 cm above the floor. Animals were allowed to reach
the closed box (20 × 20 cm) at the end of the beams (Dawes et al.,
2018).
The starting point was brightly lit with a 60W table lamp to
produce an aversive motivational stimulus. Initially, the rats were
trained for 1 week (7 days) on the beams, limited to 20 seconds (s)
to reach the box. On subsequent two attempts, the animals were
able to cross the beam in a maximum of 10 s, according to the
modified protocol of Carter et al. (2001).
The rats from each group were placed on the beam, and the
time they took to cross the beam was determined (Tărlungeanu
et al., 2016).
Sucrose Preference Test
The sucrose preference test is performed to assess the hedonic
behavior in rats. The rats were housed individually to
acquaintance with the environment for 24 h. The sucrose
solution (1.5% w/v) filled bottle was replaced with one of the
two water-filled bottles, to avoid abrupt response. During and
after the test, the sucrose volume consumed from each bottle was
noted. The sucrose preference was calculated as described earlier
(Meyerolbersleben et al., 2020).
Forced Swim Test
The FST is one of the most commonly used animal models for
assessing locomotory and antidepressant behavior. Active and
passive swimming movements are recorded in this test. The
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rats were forced to swim in a specified vessel with no exit. The
container was filled with water up to a level of 30 cm from the
bottom at 23–25°C. Reduction in the passive behavior was
inferred as an antidepressant-like effect, provided it does
not increase the general locomotor activity (Mograbi et al.,
2020).
Histopathology
The five rats from each group were decapitated; the brains were
separated immediately and postfixed in 10% V/V formalin
solution for 48 h. The longitudinal section of the hippocampus
was separated, placed in the tissue cassettes, and fixed in paraffin
block for later histopathological analysis. The histopathological
analysis was carried out by following the methods (Paradiso et al.,
2018).
Different staining methods were carried out to identify the
morphological changes in the hippocampal tissue slices, that is,
living or dead cells, accumulation of beta-amyloids, and
unwanted bodies. Hematoxylin and eosin stain (H&E), Congo
red (CR), cresyl fast violet (CFV), and Giemsa stain are some of
the staining methods.
Assessment of Serum Electrolytes
The hematological samples were collected via heart
puncture. Serum electrolytes and calcium were
determined by using serum electrolyte analyzer and assay
kit, respectively.
Expression of SV2A Gene
The whole hippocampus was separated, and total RNA was
isolated using TRIzol (Invitrogen). To estimate the mRNA
levels of the SV2A gene, the primers were designed (Table 1),
reverse-transcribed, and standardized as discussed earlier. The
ΔΔCT method was used to determine the SV2A mRNA levels in
the hippocampus of all animal groups. The data are presented as
fold change in the mRNA levels of SV2A (Vanoye-Carlo and
Gómez-Lira, 2019).
Expression of Pro- and Anti-Inflammatory
Cytokines
The expression of cytokines was determined within the
hippocampus. The hippocampus was separated and
homogenized in Trizol solution. The RNA concentration and
purity were quantified using a UV microspectrophotometer
(NanoDrop). The cDNA was prepared using MagMAX cDNA
Kit. The primers were designed using the NCBI database and
Primer 3 Plus (Table 1) (El-Missiry et al., 2019).
The RT-PCR conditions were set through the Bio-Rad
framework (Sun et al., 2019). GAPDH was used as the
housekeeping gene; its sequence is tabulated in Table 1. The
ΔΔCT method was used to determine the expression of cytokines
and transcription factors.
Statistical Analysis
The results were analyzed statistically and expressed as mean ±
S.E.M. The plots were created using Graph Pad Prism. The
Newman–Keuls multiple comparison posttest of two-way
analysis of variance (ANOVA) and one-way ANOVA followed
by post hoc Tukey’s multiple comparisons test, where applicable,
was performed to compare the test groups with the control
groups. The results were considered as non-significant (ns) if




The results were analyzed graphically by visualizing the SV2Aprotein
using PyMol software. The protein backbone is represented in
cartoon form. The ligands are shown in ball and stick
representation, and the hydrogen bonds are indicated as dashed lines.
Figure 2 represented the best docking pose of the SV2A
receptor, while LEV and PFs displayed different binding sites
to the receptor. The ligand is docked into the binding cavity of the
receptor, and the putative conformations are shown. The docking
results show that almost all residues of the compounds are
interacting with SV2A receptors, leading to favorable
interactions with LEV and PF complexes.
The binding energies of both LEV and the PF bonded system
are shown in Figure 2. The binding energies show no significant
difference in the binding affinity of quercetin compared to LEV.
The free binding energies of kaempferol and catechin were highly
significant with p < 0.0001 and p < 0.001, respectively. PyMol
visualization reveals no ligands binding to the 6AGF and 6D6T,
with the binding data shown in the supplemental file.
TABLE 1 | Forward and reverse primers are tabulated.
Molecule Forward primer Reverse primer
Interleukin 1 Beta 5′CCACTACAAAATCTGGGCGATGCA3′ 5′CAGAAGAAGAGGATGTCACTCCTCG3′
TNF alpha 5′CAAAGACAACCAACTGGTGG3′ 5′TGAGATCCATGCCATTGGCC3′
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Delay in the Onset of Seizures
In a continuous study of 14 days, on Day 0, the seizure episode
started in all rats within a minute. After 7 days of treatment, a
delay in the onset of seizure was observed in all the treated groups
(Groups 3, 4, 5, and 6). On Day 14, most of the treated rats were
normalized; that is, no seizures were observed, while in the
diseased (Group 2) untreated rats, the seizures continued even
after 14 days of disease induction. Among all the treated groups,
Group 5 (Quercetin 100 mg/kg) was found to be the most
effective in delaying the onset time. The statistical comparison
of Day 0 vs Day 7 (ns) and Day 7 vs Day 14 (p < 0.0001) revealed
that there was a significant time-dependent delay in the onset of
seizures in all phytochemical-treated groups as compared to the
standard treated drug (Figure 3A).
Number of Seizures
On day 0, the number of seizures in all the rats was more than 12
(Patel et al., 2006) during the observation time (i.e., 360 min);
after the treatment for 7 days with PFs and standard drug, there
was a significant decrease in the number of seizures. Figure 3B
shows that Group 4 treated with quercetin (100 mg/kg) is most
effective in reducing the number of seizures. On day 14, several
treated rats became seizure free, and no rat was observed having
more than 2 episodes of seizures during the observation time.
Intensity of Seizures
According to the scoring index (0–5, death at 5), we consider only
those rats that have scored 4 (rearing, falling, hind limb clonus,
and forelimb tonus) on Day 0. After the treatment for 7 days,
there was a significant attenuation in the intensity of the seizures
(Figure 3C) in the treated rats. Moreover, treatment for 7 more
days showed a significant reduction in the seizure intensity in the
standard treated groups, but in all other treated groups, there was
a statistically non-significant reduction. But still, there was an
improvement in the treatment on Day 14. While in the
diseased group, severe intense seizures were observed even on
Day 14.
Average Duration of Seizures
On Day 0, each seizure lasted for more than 2 min. On Day 7, like
all other observed parameters, there was also a significant
reduction in the duration of the observed seizures. On Day 14,
most rats have turned to be seizure free, and the seizure observing
rats had very brief episodes of seizures. Among all the treated
groups, Group 4 was still found to be very effective in treating the
seizures (Figure 3D).
Percentage Protection of Seizures
On Day 0 in all the rats, the seizures were observed, except in the
normal healthy group. The percentage protection of seizures in all
the rats was noted. After treating for 7 days, the percentage
protection was significantly increased. When comparing the
treatment of Day 7 vs Day 14, there was a significant
improvement in the protection of seizures. Among all the
treated samples, quercetin 100 mg/kg was found to be the
most effective (Figure 3E).
Behavior Tests
Light and Dark Model
It was observed that on Day 0 all the rats were diseased; therefore,
they were spending more time in the dark area than in the light
area. This depressed behavior of the rats indicated the proper
induction of the disease. After the treatment for 7 days, the
FIGURE 2 | (A) SV2A receptor (B) is the 3D structure of LEV. (C–E) Phytoflavonoids (kaempferol, quercetin, and catechin) (F–I) showing the protein ligand
interaction of LEV, kaempferol, quercetin, and catechin. (J) Graph of the binding energies one-way ANOVA (Moghbelinejad et al., 2016; Verrotti et al., 2020) F  8.130
followed by post hoc Bonferroni’s multiple comparison test.*p < 0.01. **p < 0.05, ***p < 0.0005, and ****p < 0.0001.
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FIGURE 3 | (A) Delay in the onset of seizures, Day 0: onset of seizures was less than a minute after induction. At Days 7 and 14 of treatment, onset was delayed in
each group up to 60 min and/or up to 360 min (maximum time), respectively. ANOVA, F (5/42)  15.68, confirmed significant improvement at Day 14 among the groups
and also between two time points. While at time points Day 7 and Day 14, there was no significant difference among standard treatment and phytoflavonoid-treated
groups. (B) Number of seizures, Day 0: number of seizures in all the rats was more than 13; at Day 7 of treatment in the treatment group, there was a significant
reduction in the number of seizures. On Day 14, the number of seizures was significantly reduced as compared to both Day 0 and Day 7 until 360 min (6 h). ANOVA, F (5/
42)  88.26, confirmed significance improvement at day 14 among the groups and also between two time points. (C) Intensity of seizures, Day 0: Intensity of seizures in
all the rats was more than 3; at Day 7 of treatment in the treatment group, there was a significant reduction in the intensity of seizures; at Day 14, the intensity of seizures
was significantly reduced as compared to Days 0 and 7 until 360 min (6 h). ANOVA, F (5/42)  16.25, confirmed significant improvement at Day 14 among the groups
and also between two time points. (D) Average duration of seizures, Day 0: Average duration of seizures in all the rats was more than 2 min per seizure; at Day 7 of
treatment in the treatment group, there was a significant reduction in the duration of seizures; at Day 14, the duration of seizures was significantly reduced as compared
to Days 0 and 7 until 360 min (6 h). ANOVA, F (5/42)  139.4, confirmed significant improvement at Day 14 among the groups and also between two time points. (E)
Percentage protection of seizure, Day 0: all the groups observed seizures except the normal group. At Days 7 and 14 of treatment, seizures were protected in all the
groups, but no protection was observed in the diseased group during the observation time. ANOVA, F (5/42)  60.30, confirmed significant improvement at Day 14
among the groups and also between two time points. While at time points Day 7 and Day 14, there was a significant improvement among the standard treatment and PF-
treated groups. p < 0.0001. **p < 0.05, ***p < 0.0005, and ****p < 0.0001 (Newman–Keuls multiple comparison post-test Day 0 vs Day 7 * and Day 7 vs Day 14#).
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FIGURE 4 | (A) Light and dark model, Day 0: diseased rats were non-significant in all the groups showing the proper induction of the disease in all the rats. 7- and
14-Day treatment in both standard treated and others; phytochemicals (100 mg/kg) significantly reduced the time spent in the darker area, and more time is spent in the
light area. ANOVA, F (5/42)  2.33, confirmed significant improvement in the behavior at Day 14 among the groups and also between two time points (Day 7 vs Day 14#)
(Continued )
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diseased group was displaying the same behavior, while in Group
3 (standard treated group), the rats were spending more time in
the light area than in the dark area. A similar effect was also
observed in Groups 4, 5, and 6 (PF 100 mg/kg) treated groups.
After the treatment for 14 days, the diseased rats were still
spending more time in the darker areas, whereas Group 3 and
Groups 4,5, and 6 (PF 100 mg/kg) treated rats spent significantly
less time in the dark area than in the light area (Figure 4A).
Among the other treated groups, Group 4 is found to be most
effective on Day 7. On Day 14, the treatment was not statistically
significant as compared to that on Day 7, while the treatment was
highly significant as compared to the diseased group, that is, Day
0. Henceforth, quercetin 100 mg/kg treated group 4 displayed
better behavior than the standard treated groups.
Elevated Plus Maze
OnDay 0, all the diseased rats were spending non-significantlymore
time in the closed arm, confirming the disease is uniformly induced
in all the rats exceptGroup 1 (normal healthy rats). OnDay 7, Group
3 standard drug (LEV 21mg/kg) rats were significantly spending
more time in the open arm, and the PF-treated groups were also
behaving identically. In comparison between Days 0 and 14, there
was also a significant improvement in all the treatment groups.
However, by comparingDay 7 vsDay 14, statistically non-significant
differences in behavior were observed along with an increase in the
open arm stay. Among all the PF-treated groups, quercetin
(100mg/kg) was found to be the most effective (Figure 4B).
Rotarod Test
This test was performed to recognize motor coordination in rats.
Normal rats remained at the rotating rod up to the speed of 40
revolutions per minute (RPM). Stay time at the rod was more
than 3 min. However, the diseased rats were not capable to
maintain balance on the rotating rod at a speed of 20 rpm. On
Day 0, all the groups were statistically significant, confirming that
the disease has been induced, while the normal rats still showed
good balance. After 7 days of treatment, there was an incredible
improvement in the motor coordination of treated animals in
both the standard and PF-treated groups (Groups 3, 4, 5, and 6).
Both the treated groups displayed a very significant reinforcement
in the normal behavior. Similarly, on Day 14 as compared to Day
0, the rats were showing a significant improvement in the
symptoms of epilepsy. In comparing Day 7 vs Day 14,
although the improvement in the behavior was found, the
results were not significant. Quercetin 100 mg/kg was found to
be the most effective in the reinforcement of normal healthy
behavior (Figure 4C).
Infrared Actimeter
In this test, we quantified the slow movements as well as the fast
movements. Normal rats showed normal movements
(Figure 4D), while in the diseased group, the slow movements
were increased, and fast movements were decreased as compared
to those of the normal rats. After the treatment for 7 days in the
standard (LEV 21 mg/kg) treated groups, a significant increase in
fast movements and decrease in slow movements was observed
compared to the normal rats. However, the PF (100 mg/kg)
treated groups were significantly the best. The catechin
100 mg/kg treated group showed better results among all the PFs.
Beam Walking Test
In the diseased rats, there was a significant delay in passing the
rod as compared to that of the normal rats. After the treatment for
7 days in the standard treated group (LEV 21 mg/kg), there was a
significant delay in the time to pass the beam. However, in the PF
(100 mg/kg) treated groups, there was a very significant
(p < 0.0001) reinforcement of the normal limb coordination.
After the treatment for 14 days, there was a significant
(p < 0.0001) improvement in normalizing the epileptic
symptoms. By comparing Day 7 with Day 14, a significant
improvement was found in the gait-related behavior in the
standard and PF-treated groups with p < 0.01 and p < 0.0005,
respectively. The catechin 100 mg/kg treated group behaved well
among all the treated groups (Figure 4E).
Sucrose Preference Test
The diseased rats displayed diminished sucrose preferences. On
Day 0, the disease was induced uniformly, except the normal
FIGURE 4 | was found to be statistically non-significant. (B) Elevated plus maze, Day 0: diseased rats were non-significant in all the groups showing the
proper induction of the disease in all the rats. 7- and 14-Day treatment in both standard treated and others; phytochemicals (100 mg/kg) significantly reduced the
time spent in the closed arm, and more time is spent in the open arm. ANOVA, F (5/42)  2.33, confirmed significant improvement in the behavior at Day 14 among
the groups and also between two time points. Day 7 vs Day 14 was found to be statistically non-significant. (C) Rotarod test, Day 0: diseased rats were non-
significant in all the groups showing the proper induction of the disease in all the rats. 7- and 14-Day treatment in both standard treated and others; phytochemicals
(100 mg/kg) significantly improved the coordination of the rats on the rotarod. ANOVA, F (5/42)  39.34, confirmed significant improvement in the behavior at Day
14 among the groups. Day 7 vs Day 14was found to be statistically non-significant. (D) Infrared actimeter, Day 0: diseased rats were non-significant in all the groups
showing the proper induction of the disease in all the rats. 7- and 14-Day treatment in both standard treated and others; phytochemicals (100 mg/kg) significantly
improved the locomotion of the rats on the IR actimeter. ANOVA, F (5/42)  54.27, confirmed significant improvement in the behavior at Day 14 among the groups.
Day 7 vs Day 14 was found to be statistically non-significant. (E) Beam walking test, Day 0: diseased rats were non-significant in all the groups showing the proper
induction of the disease in all the rats. 7- and 14-Day treatment in both standard treated and others; phytochemicals (100 mg/kg) significantly improved the limb
coordination of the rats on the walking rod. ANOVA, F (5/42)  139.4, confirmed significant improvement in the behavior at Day 14 among the groups. Day 7 vs Day
14 was found to be statistically non-significant. (F) Sucrose preference test, Day 0: diseased rats were non-significant in all the groups showing the proper induction
of the disease in all the rats. 7- and 14-Day treatment in both standard treated and others; phytochemicals (100 mg/kg) significantly enhanced sucrose containing
water. ANOVA, F (5/42)  7.58, confirmed significant improvement in the behavior at Day 14 among the groups and also between two time points (Day 7 vs Day 14#)
was found to be statistically less significant. (G) Forced swim test, Day 0: diseased rats were non-significant in all the groups showing the proper induction of the
disease in all the rats. 7- and 14-Day treatment in both standard treated and others phytochemicals (100 mg/kg) significantly increase the swimming time. Two-way
ANOVA, F (5/42)  12.45, confirmed significant improvement in the behavior at Day 14 among the groups and also between two time points. p < 0.0001. *p < 0.01,
**p < 0.05, ***p < 0.0005, and ****p < 0.0001 (Newman–Keuls multiple comparison post-test Day 0 vs Day 7 * and Day 0 vs Day 14*).
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group. Over the course of 7 days of treatment, the standard
treated and PF-treated rats showed significant improvement in
the sucrose preference. Upon further treatment of 7 days, there
was a significant improvement in the sucrose preference. In
comparing Day 0 vs Day 7 and Day 0 vs Day 14 (p < 0.0001),
there was a highly significant improvement, while the normal
control and diseased groups remain non-significant. However, by
comparing Day 7 vs Day 14, a significant improvement was also
observed (p < 0.005) (Figure 4F).
Forced Swim Test
The swim test involves the monitoring of active mobility and
drowning of rats. It was observed that on Day 0, all the rats started
drowning after less than 40 s, while normal rats kept swimming
for more than 60 s. After the treatment of 7 days with standard
drugs and PFs, there was a significant improvement in swimming.
Comparing Day 0 vs Day 7 and Day 0 vs Day 14, a highly
significant improvement was observed, while the normal control




Showing the hippocampal cross-sectional view of the brain tissue,
the hematoxylin stains cell nuclei blue, and eosin stains the
extracellular matrix and cytoplasm pink. Group 1 is showing
the intact cellular morphology, while there is significant damage
destruction of the cells seen in Group 2. However, treated groups
FIGURE 5 | Hematoxylin and eosin staining: Group 1 is showing normal cells in Groups 2, 3, 4, 5, and 6 and displaying the damaged cells. Cresyl fast violet (CFV)
staining: Group 1 Nissl bodies are not seen; however, in Group 2, the Nissl bodies ( ) are highly prominent. In group 3 these bodies are not seen, in PF treated groups very
few Nissl bodies are stained. Congo red staining CR: Group 1 neuropils and amyloid bodies are not stained, while in Group 2, neuropils and amyloid bodies ( ) are seen.
Neuropils are not seen in any other group; however, F amyloid bodies are stained. Giemsa staining: Group 1 glial cells ( ) are visible. In Group 2, glial cells are not
visible, and it contains neuropils. In Groups 2,3,4,5, and 6, glial cells are undamaged.
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(Groups 3, 4, 5, and 6) are showing the prevention of cellular
destruction among the different groups. Group 5 is showing the
normal cellular density (Figure 5).
Cresyl Fast Violet
CFV stained the Nissl proteins. The Nissl proteins are displayed
in pink to violet color. Group 2 is presented with extreme
peripheral and mild centrally stained proteins. The observed
intense chromatolytic change in the hippocampal cells was
prevented by the treatment in the treated groups (Figure 5).
Congo Red Staining
The CR-stained hippocampal cells are shown in Figure 3. The
stained sections of hippocampal cells exhibited dull red staining
of the neurons as well as the neuropil. Congophilic masses of
irregular sizes were seen. Amyloid deposits are visible as red to
pink-red, the nucleus is blue, and all other tissues did not stain
and can be seen by an ordinary light microscope. Inflammatory
cells and granular basophilic debris were stained dark blue to
black. Group 2 is showing both dull and bright red neuropil and
amyloid proteins, respectively. While in the treated groups
(Groups 3, 4, 5, and 6), the chromolytic changes were not
observed (Figure 5).
Giemsa Staining
The neurons appear red-violet, while cerebellar granules are seen
as deep blue; however, the glial cells are visible in pale blue. At
high magnification, the nucleus of glial cells is stained blue and
scarce cytoplasm red-violet. The astrocyte nuclei are stained
homogeneously, while the neuropil is seen as bright pink,
giving an enhancing framework for the cells. Non-myelinated
and myelinated fibers will not be stained.
Group 1 displays glial cells having normal nuclei, cytoplasm,
and astrocytes include normal neuropils. However, group 2 is
displaying the ruptured nucleated cell. Likewise, the treated
groups are showing lesser damage to the hippocampal cells
than the diseased group (Figure 5).
Assessment of Sodium, Potassium,
Chloride, and Calcium Levels
The results showed significant fluctuations in the diseased groups;
however, treatment with PFs regularizes the levels of these
electrolytes as also shown by the standard treated group
(Table 2).
mRNA Expression of SV2A
SV2A is highly expressed in hippocampal tissue in the diseased
states. The expression of the receptors was significantly reduced.
After the treatment for 14 days, standard drug and PFs showed a
significant amplification in the RNA (Figure 6).
mRNA Expression of Pro-Inflammatory
Cytokines
Expression levels of pro-inflammatory cytokines such as TNF-α,
IL-6, IL-1 beta, and NF-LB were significantly up-regulated in
diseased group B as compared to that of normal group A. The
treatment with LEV and PF groups (C, D, E, and F), respectively,
caused a significant reduction in the expression levels. Similarly,
compared with Group A, it revealed that non-significant
difference was observed in Groups C, D, E, and F (Figure 7).
TABLE 2 | Levels of sodium potassium chloride and calcium levels: Group A (normal control), Group B (PTZ 25 mg/kg), Group C (LEV 21 mg/kg), Group D (kaempferol
21 mg/kg), Group E (quercetin 100 mg/kg), and Group F (catechin 100 mg/kg). Statistical analysis was done through one-way analysis of variance (ANOVA) trailed by
Tukey’s post hoc test for all groups. The results are considered significant p if p < 0.005. ppp < 0.05 and pppp < 0.05. Results were compared in a column with the respective
diseased groups.
Groups Sodium (mEq/mmol) Potassium (mEq/mmol) Chloride (mEq/mmol) Calcium (mEq/mmol)
A 135 ± 5.5** 4.0 ± 1.25** 105 ± 2.2* 12 ± 1.5**
B 155 ± 5 9.6 ± 0.8 110 ± 2.5 6 ± 0.5
C 135 ± 2** 5.0 ± 0.5* 104 ± 3* 11 ± 0.5**
D 140 ± 5* 6.4 ± 0.2* 105 ± 4* 11 ± 1.0**
E 142 ± 3* 5.2 ± 0.25* 106 ± 2ns 12 ± 0.5***
F 138 ± 4* 5.8 ± 0.84* 108 ± 5ns 11 ± 0.5**
FIGURE 6 | Graphical representation of the mean ± SD relative
expression levels of SV2A. The treatment of PF significantly improves the
protein expression. The data were analyzed by one-way ANOVA followed by
Tukey’s post hoc test. Comparison of Group A vs B, C, D, E, and F
denoted by (#), while Group B vs C, D, E, and F is denoted by (*). *p < 0.05.
**p < 0.01, ***p < 0.0005, and ****p < 0.0001.
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Expression of Anti-Inflammatory Cytokines
Anti-inflammatory cytokines including IL-10, IL-1Ra, and IL-4
levels were found significantly down-regulated in diseased group
B as compared to that of normal group A (44.49 ± 6.39). These
reduced levels were found up-regulated after the treatment with
LEV and PFs.
By comparing normal group A with treated groups (C, D, E,
and F), IL-10 groups D, E, and F had p < 0.01 and C had p < 0.05
levels significant. In case of cytokine IL-1Ra Groups C and Dwere
non-significant, while in Groups E and F (p < 0.05) significance
was observed likewise in IL-4 Group D (p < 0.05) significance was
observed, and the rest of the treated groups were non-significant
(Figure 8).
DISCUSSION
Epileptic seizures are triggered by the imbalance between the
activity of excitatory and inhibitory neurotransmitters (Higuera-
Matas et al., 2012). The etiology of seizures is unknown; however,
certain stimuli can provoke, initiate, or augment the number,
duration, frequency, and intensity of seizures (Ancelin et al.,
2007). Other pathogenetic factors include the up-regulation of the
pro-inflammatory cytokines (TNF α, interleukin (IL)-1β, and IL-
6) and down-regulation of the anti-inflammatory cytokines (IL-1
receptor antagonist, IL-4, and IL-10) in the hippocampal tissues.
Likewise, up-regulation of the transcription factor NFkB has also
been observed (Šutulović et al., 2018).
Molecular docking of both LEV and PFs to the active site of
the SV2A receptor was performed. Docking poses for both
proteins were saved for each complex and graphically viewed
to identify the ligand–protein interactions. Both ligands
developed similar types of interactions at the dynamic site
of the protein; at this site, it formed similar H-bond
interactions with adjacent residues (Jain, 2003). The
docking results showed the involvement of receptor
residues, that is, Lys 333, Ala 396, and Leu 281, in docking
all the ligands. This elucidates that the binding sites on SV2A
for LEV and PFs are apparently similar to each other, which
further signifies that both ligands probably possess the same
therapeutic efficacy. Although molecular docking
investigations only outline the binding of ligands with the
protein, the solvent, temperature, and pressure effects could
not be considered (Fogolari et al., 2003). Moreover, it outlines
the possible drug targeting sites on this protein as well as their
role in stabilizing ligand–protein interactions. Further
FIGURE 7 |Graphical representation of the mean ± SD relative expression levels of (A) TNF-α, (B) IL-6, (C) IL1 beta, and (D)NFkB. The treatment of PF significantly
suppresses the pro-inflammatory cytokines. The data were analyzed by one-way ANOVA followed by Tukey’s post hoc test. Comparison of Group A vs B, C, D, E, and F
denoted by (#), while Group B vs C, D, E, and F is denoted by (*). *p < 0.05. **p < 0.01, ***p < 0.0005, and ****p < 0.0001.
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org November 2021 | Volume 9 | Article 75495212
Ahmed et al. Phytoflavonoids in the Treatment of Epilepsy
research on the pharmacokinetics and pharmacodynamics of
PFs will help to underpin the downstream signaling pathways.
PTZ is used to develop chronic chemically kindled epilepsy
models. PTZ is GABA-A receptor antagonist. It is a tool to study
hippocampal foci–induced epilepsy and its effects, by altering the
GABA and glutamate concentration. SV2A is concentrated in the
hippocampus. In the principal cell layers (granular and
pyramidal), the SV2A protein is localized to GABAergic and
glutamatergic terminals. SV2A is ubiquitously expressed in the
entire hippocampus; it established an association with excitatory
or inhibitory terminals, and this could lead to maintaining the
balance of excitatory/inhibitory neurotransmitters. SV2A belongs
to a unique family of proteins that is exclusive to secretory vesicles
that endure calcium exocytosis (Ciruelas et al., 2019).
Due to the excessive neuronal firing, generalized seizures were
observed in the rats. Oxidative stress is an important mechanism
in several neurological disorders (Pearson-Smith and Patel,
2017). Oxidative stress is experienced after the first episode of
seizure, which then leads to epileptogenesis (Pearson-Smith et al.,
2017).
Unlike conventionally used AEDs, LEV did not show
effectiveness in the primitively employed acute epilepsy animal
models. However, it showed effectiveness in the chronically
kindled epilepsy model. The SV2A binding affinity of LEV
and its derivatives correlated strongly with their binding
affinity in the brain, as well as with their ability to protect
against seizures. The specific effect of LEV binding to SV2A
proves that there is a reduction in the rate of vesicle release (Yang
et al., 2007). Flavonoids may cause the facilitation of the
GABAergic and glutamatergic neurotransmission. Flavonoids
are antioxidants and can cross the blood–brain barrier (ref).
Quercetin has been shown to antagonize GABA-A receptors
(Nassiri-Asl et al., 2016). Catechin could enhance the spatial
cognitive ability in normal animals. Recent reports demonstrate
that catechin could attenuate oxidative damage in the brain
ischemia model. These properties enhance the probability of
catechin as a substance used in treating epileptic seizures
(Wang et al., 2016).
On Day 0, all the rats were completely kindled as shown in the
results of the observed parameters and verified by the behavior tests
as compared to Group 1 (normal rats). After the treatment for 7
days, PFs displayed comparable results with Group 3 (LEV treated).
Furthermore, treatment was continued for 7more days, that is, up to
14 days. Kaempferol (Group 4) and quercetin (Group 5) treated
groups demonstrated better results than LEV (Group 3) treated
groups. In all the treated groups, the onset time, intensity, number,
average duration of seizure, and percentage protection of seizures
were ameliorated in comparison to LEV.
PTZ-induced seizures are also characterized as impairment in
spatial learning ability, reference memory, coordination, and
locomotion in the rat model (ref). The hippocampus plays its role
in learning and memory, especially in spatial cognitive learning,
locomotion, and coordination (Malone et al., 2008). Changes in the
synapses have a direct impact on the performance of rats in rotarod,
IR actimeter, beam walking test, elevated plus maze, and light and
darkmodel. After 14 days of treatment, all the rats were behaving like
normal rats. Epilepsy prompts anxiety and depression (Aguilar et al.,
2018). This behavior was evident in the diseased rats. Furthermore,
elevated plus maze and light and darkmodels were used to recognize
the anxiety and depression in the rat model. Similar to LEV, these
PFs have the potential to decrease epilepsy-induced depression and
anxiety. A markedly reduced interest or pleasure in activities
previously considered pleasurable is one of the main symptoms
in neurodegenerative diseases (ref). The sucrose preference test has
FIGURE 8 | Graphical representation of the mean ± SD relative
expression levels of (A) IL-1Ra, (B) IL-4, and (C) IL-10. The treatment of PF
significantly suppresses the pro-inflammatory cytokines. The data were
analyzed by one-way ANOVA followed by Tukey’s post hoc test.
Comparison of Group A vs B, C, D, E, and F denoted by (#), while Group B vs
C, D, E, and F is denoted by (*). *p < 0.05. **p < 0.01, ***p < 0.0005, and ****p <
0.0001.
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explicitly highlighted the cognitive system in sucrose preference. This
behavior was evident in the diseased rats. These tests are used to
identify the expression of neurodegeneration due to the disease.
Furthermore, these tests were tested to recognize anxiety and
depression symptoms due to chronic epileptic seizures. Similar to
LEV, these PFs have the potential to decrease epilepsy-induced
depression and anxiety.
Histopathological analysis of the brain tissues revealed that
these flavonoids have the potential to decrease or prevent cellular
damage. These PFs are antioxidants in nature. Besides that, CFV
stained the Nissl bodies in the brain. These bodies were formed in
neuronal cytoplasm as a result of neuronal inflammation. The
bodies were seen in Group 2 (diseased), whereas these bodies
were not seen in the treated groups. It is apparent that there was a
significant reduction in neuronal inflammation. CR stain
confirms the amyloidosis; the amyloid bodies were visible in
Group 2 (diseased). However, these were not visible in the treated
and normal groups. In this regard, LEV has been shown to be
effective against Alzheimer’s pathology that is characterized by
the accumulation of the beta-amyloid in the neurons (Inaba et al.,
2019). This unique drug also possesses anti-inflammatory effects
(Gulcebi et al., 2018). Giemsa-stained cells displayed the neurons,
glial cells, and astrocytes. The diseased group confirms the
presence of damaged neurons, the potential flavonoid
diminution of the neuronal damage. It has been observed by
the molecular docking results that these flavonoids have a binding
affinity toward the SV2A receptor.
The seizure-induced brain damage causes cerebral inflammation,
and it initiates the epileptogenic effects (Stienen et al., 2011). Pro-
and anti-inflammatory cytokines are highly expressed in the
hippocampus. The hippocampal foci were formed in the epileptic
rats because of PTZ-induced epilepsy. The expression of these
cytokines was accessed in the hippocampal tissue. PTZ formed
the epileptic foci in the hippocampus. The hippocampal lesions
cause the up-regulation and down-regulation of pro-inflammatory
cytokines (TNF-α, IL-1 beta, and IL-6), and anti-inflammatory
cytokine (IL1Ra, IL-4, and IL-10) expression, respectively. Pro-
inflammatory cytokines stimulate the chronic release of excitable
neurotransmitters and inhibit the uptake of these neurotransmitters
(Al-Shorbagy et al., 2013). The LEV and phytoflavonoids down- and
upregulate the pro-inflammatory and anti-inflammatory cytokines,
respectively. We also assessed the expression of the SV2A gene. This
receptor is most concentrated in the hippocampal regions. In the
diseased conditions, the SV2A gene is underexpressed (Vanoye-
Carlo and Gómez-Lira, 2019). PFs and LEV significantly enhanced
the SV2A gene expression. Like LEV, PF not only regulates the
cytokines but also controls the expression of the receptor. Extensive
in vitro studies including electroencephalography (EEG) and clinical
studies are required to establish the role of these PFs in epilepsy.
CONCLUSION
In silico studies prove that these PFs have the binding potential
toward the SV2A receptor. In vivo findings showed that these PFs
have the potential to modulate the immune response and can be
an important therapeutic alternative for the treatment of epilepsy.
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